|Slideshows|March 15, 2021

10 Facts About Geriatric Pharmacotherapy

It is important to monitor and alter psychotropic medications and dosages in older patients as needed. This slideshow serves as quick reference on the effects of pharmacokinetic and pharmacodynamic changes in the elderly.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Glyph Allopregnanolone for Major Depressive Disorder Meets Phase 1 Endpoints

ByJessica Walters

September 9th 2026

Choosing Sexual Function-Sparing Medications

ByJoseph F. Goldberg, MD,Anita H. Clayton, MD

September 9th 2026

Anita Clayton, MD, on Diagnosing and Discussing Sexual Dysfunction

ByJoseph F. Goldberg, MD,Anita H. Clayton, MD

September 8th 2026

Brain Trust: Anita H. Clayton, MD, on Diagnosing and Treating Sexual Dysfunction

ByJoseph F. Goldberg, MD,Anita H. Clayton, MD

September 2nd 2026

The Year So Far in GLP-1s: What Psychiatric Clinicians Need to Know

ByJessica Walters

August 31st 2026

Latest CME

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

10 Facts About Geriatric Pharmacotherapy

Related Content

Glyph Allopregnanolone for Major Depressive Disorder Meets Phase 1 Endpoints

Choosing Sexual Function-Sparing Medications

Anita Clayton, MD, on Diagnosing and Discussing Sexual Dysfunction

Brain Trust: Anita H. Clayton, MD, on Diagnosing and Treating Sexual Dysfunction

The Year So Far in GLP-1s: What Psychiatric Clinicians Need to Know

Latest CME

Jersey City Psychiatry

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Trending on Psychiatric Times

DT120 (Lysergide) ODT Receives Breakthrough Therapy Designation for Treatment of MDD

New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose

The Postmodern Worldview and Contemporary Psychiatry

New Phase 3 Data on Oveporexton for Narcolepsy Type 1

Choosing Sexual Function-Sparing Medications